The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
Open accessAbstract
A better knowledge of the complex interactions between cancer cells and the immune system has led to novel immunotherapy approaches. Treatment with selective anti-PD1, anti-PD-L1 and/or anti-CTLA-4 monoclonal antibodies (mAbs) has been a revolution in the therapeutic scenario of several cancer types, with the highest clinical efficacy in melanoma and in lung cancer. Colorectal cancer is one of the tumours in which immunotherapy has been shown less effective. Whereas in deficient mismatch repair (MMR) or in highly microsatellite instable (MSI-H) metastatic colorectal cancer there is clear clinical evidence for a therapeutic role of immune checkpoint inhibitors, the vast majority of patients with proficient MMR or with microsatellite stable (MSS) tumours do not benefit from immunotherapy. Defining the molecular mechanisms for immunogenicity in metastatic colorectal cancer is needed in order to develop predictive biomarkers and effective therapeutic combination strategies. A major challenge will be to identify, among the heterogeneous spectrum of this disease, those patients with specific tumour and tumour infiltrating stroma molecular and functional characteristics, that could be effectively treated with immunotherapy. In this review, we discuss the role of immune response in the context of metastatic colorectal cancer. We summarize the available clinical data with the use of anti PD-1/PD-L1 mAbs as single agents or in combination with anti CTLA-4 mAbs in MSI-H patients. Finally, we address the challenges and the potential strategies for rendering the more frequent microsatellite stable (MSS) tumours "immune-competent" and, therefore, amenable for effective immunotherapy interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675
Self-citationDurvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Self-citationPembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Microsatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
Kang, Y.-K., Boku, N., Satoh, T., Ryu, M.-H., Chao, Y., Kato, K., Chung, H. C., Chen, J.-S., Muro, K., Kang, W. K., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31827-5 · Cited by 2,252
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Pagès, F., Mlecnik, B., Marliot, F., Bindea, G., Ou, F.-S., Bifulco, C., Lugli, A., Zlobec, I., Rau, T. T., Berger, M. D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30789-x · Cited by 2,075
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851
Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737
Cohen, E. E. W., Soulières, D., Le Tourneau, C., Dinis, J., Licitra, L., Ahn, M.-J., Soria, A., Machiels, J.-P., Mach, N., Mehra, R., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31999-8 · Cited by 1,709
Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism
Munn, D. H., Shafizadeh, E., Attwood, J. T., Bondarev, I., Pashine, A., & Mellor, A. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1363 · Cited by 1,623
An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
Mezrich, J. D., Fechner, J. H., Zhang, X., Johnson, B. P., Burlingham, W. J., & Bradfield, C. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903670 · Cited by 1,601
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer)
Hampel, H., Frankel, W. L., Martin, E., Arnold, M., Khanduja, K., Kuebler, P., Nakagawa, H., Sotamaa, K., Prior, T. W., Westman, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043146 · Cited by 1,408
Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G. A., Moiseyenko, V., Ferry, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8201 · Cited by 1,402
Tumor Microsatellite Instability and Clinical Outcome in Young Patients with Colorectal Cancer
Gryfe, R., Kim, H., Hsieh, E. T. K., Aronson, M. D., Holowaty, E. J., Bull, S. B., Redston, M., & Gallinger, S. (2000) · New England Journal of Medicine · doi:10.1056/nejm200001133420201 · Cited by 1,388
Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L. P., Feuerhake, F., Klaman, I., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.016 · Cited by 1,384
Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., & Ghiringhelli, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3690 · Cited by 1,245
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140559 · Cited by 1,179
Immunogenic death of colon cancer cells treated with oxaliplatin
Tesniere, A., Schlemmer, F., Boige, V, Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., et al. (2010) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,173
Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,158
Whole Body Irradiation—Radiobiology or Medicine?
Mole, R. H. (1953) · The British Journal of Radiology · doi:10.1259/0007-1285-26-305-234 · Cited by 1,123
Microsatellite Instability in Colorectal Cancer-the Stable Evidence
Vilar, E., & Gruber, S. B. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.237 · Cited by 1,063
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Motz, G. T., Santoro, S. P., Wang, L.-P., Garrabrant, T., Lastra, R. R., Hagemann, I. S., Lal, P., Feldman, M. D., Benencia, F., & Coukos, G. (2014) · Nature Medicine · doi:10.1038/nm.3541 · Cited by 1,035
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
Dienstmann, R., Vermeulen, L., Guinney, J., Kopetz, S., Tejpar, S., & Tabernero, J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.126 · Cited by 1,021
Tabernero, J., Yoshino, T., Cohn, A. L., Obermannova, R., Bodoky, G., Garcia-Carbonero, R., Ciuleanu, T.-E., Portnoy, D. C., Van Cutsem, E., Grothey, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70127-0 · Cited by 952
Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.67 · Cited by 928
Molecular Predictors of Survival after Adjuvant Chemotherapy for Colon Cancer
Watanabe, T., Wu, T.-T., Catalano, P. J., Ueki, T., Satriano, R., Haller, D. G., Benson, A. B., & Hamilton, S. R. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104193441603 · Cited by 888
Feasibility of Screening for Lynch Syndrome Among Patients With Colorectal Cancer
Hampel, H., Frankel, W. L., Martin, E., Arnold, M., Khanduja, K., Kuebler, P., Clendenning, M., Sotamaa, K., Prior, T., Westman, J. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5950 · Cited by 876
Targeting immunosuppressive adenosine in cancer
Vijayan, D., Young, A., Teng, M. W. L., & Smyth, M. J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.86 · Cited by 840
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Emens, L. A., & Middleton, G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0064 · Cited by 831
Immunohistochemistry Versus Microsatellite Instability Testing in Phenotyping Colorectal Tumors
Lindor, N. M., Burgart, L. J., Leontovich, O. N., Goldberg, R. M., Cunningham, J. M., Sargent, D. J., Walsh-Vockley, C., Petersen, G. M., Walsh, M. D., Leggett, B., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.4.1043 · Cited by 817
Carcinoembryonic Antigen as a Marker for Colorectal Cancer: Is It Clinically Useful?
Duffy, M. J. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.4.624 · Cited by 794
Van Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789
Self-citationEbert, P. J. R., Cheung, J., Yang, Y., McNamara, E., Hong, R., Moskalenko, M., Gould, S. E., Maecker, H., Irving, B. A., Kim, J. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.024 · Cited by 713
Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo
Villadangos, J. A., & Schnorrer, P. (2007) · Nature Reviews Immunology · doi:10.1038/nri2103 · Cited by 702
Veigl, M. L., Kasturi, L., Olechnowicz, J., Ma, A., Lutterbaugh, J. D., Periyasamy, S., Li, G.-M., Drummond, J., Modrich, P. L., Sedwick, W. D., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8698 · Cited by 648
DNA Damage and Repair Biomarkers of Immunotherapy Response
Mouw, K. W., Goldberg, M. S., Konstantinopoulos, P. A., & D'Andrea, A. D. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0226 · Cited by 645
Shia, J. (2008) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.080031 · Cited by 643
Brandacher, G., Perathoner, A., Ladurner, R., Schneeberger, S., Obrist, P., Winkler, C., Werner, E. R., Werner-Felmayer, G., Weiss, H. G., G√∂bel, G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1966 · Cited by 614
The significance of OX40 and OX40L to T‐cell biology and immune disease
Croft, M., So, T., Duan, W., & Soroosh, P. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00766.x · Cited by 604
Becht, E., de Reyniès, A., Giraldo, N. A., Pilati, C., Buttard, B., Lacroix, L., Selves, J., Sautès-Fridman, C., Laurent-Puig, P., & Fridman, W. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2879 · Cited by 590
Ready, N., Hellmann, M. D., Awad, M. M., Otterson, G. A., Gutierrez, M., Gainor, J. F., Borghaei, H., Jolivet, J., Horn, L., Mates, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01042 · Cited by 581
Eng, C., Kim, T. W., Bendell, J., Argilés, G., Tebbutt, N. C., Di Bartolomeo, M., Falcone, A., Fakih, M., Kozloff, M., Segal, N. H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30027-0 · Cited by 577
Self-citationReynders, K., Illidge, T., Siva, S., Chang, J. Y., & De Ruysscher, D. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.03.011 · Cited by 574
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression
Ohm, J. E., Gabrilovich, D. I., Sempowski, G. D., Kisseleva, E., Parman, K. S., Nadaf, S., & Carbone, D. P. (2003) · Blood · doi:10.1182/blood-2002-07-1956 · Cited by 538
Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L. D., Carbone, D. P., & Gabrilovich, D. I. (1998) · PubMed · Cited by 530
Angelova, M., Charoentong, P., Hackl, H., Fischer, M. L., Snajder, R., Krogsdam, A. M., Waldner, M. J., Bindea, G., Mlecnik, B., Galon, J., et al. (2015) · Genome Biology · doi:10.1186/s13059-015-0620-6 · Cited by 522
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
Koopman, M., Kortman, G. A. M., Mekenkamp, L., Ligtenberg, M. J. L., Hoogerbrugge, N., Antonini, N. F., Punt, C. J. A., & van Krieken, J. H. J. M. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604867 · Cited by 515
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial
Vermorken, J. B., Claessen, A. M., van Tinteren, H., Gall, H. E., Ezinga, R., Meijer, S., Scheper, R. J., Meijer, C. J., Bloemena, E., Ransom, J. H., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07186-4 · Cited by 504
Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L., Carbone, D. P., & Gabrilovich, D. I. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.3.1224 · Cited by 481
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
Hegde, P. S., Wallin, J. J., & Mancao, C. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.002 · Cited by 453
Liu, L., Mayes, P. A., Eastman, S., Shi, H., Yadavilli, S., Zhang, T., Yang, J., Seestaller-Wehr, L., Zhang, S.-Y., Hopson, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2339 · Cited by 446
Cremolini, C., Rossini, D., Dell’Aquila, E., Lonardi, S., Conca, E., Del Re, M., Busico, A., Pietrantonio, F., Danesi, R., Aprile, G., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5080 · Cited by 424
Microsatellite Instability Testing and Its Role in the Management of Colorectal Cancer
Kawakami, H., Zaanan, A., & Sinicrope, F. A. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0348-2 · Cited by 418
Barlesi, F., Vansteenkiste, J., Spigel, D., Ishii, H., Garassino, M., de Marinis, F., Özgüroğlu, M., Szczesna, A., Polychronis, A., Uslu, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30673-9 · Cited by 399
Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses
Young, A., Ngiow, S. F., Barkauskas, D. S., Sult, E., Hay, C., Blake, S. J., Huang, Q., Liu, J., Takeda, K., Teng, M. W. L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.025 · Cited by 388
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
Mehnert, J. M., Panda, A., Zhong, H., Hirshfield, K., Damare, S., Lane, K., Sokol, L., Stein, M. N., Rodriguez-Rodriquez, L., Kaufman, H. L., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84940 · Cited by 380
D’Angelo, S. P., Russell, J., Lebbé, C., Chmielowski, B., Gambichler, T., Grob, J.-J., Kiecker, F., Rabinowits, G., Terheyden, P., Zwiener, I., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0077 · Cited by 377
A panoply of errors: polymerase proofreading domain mutations in cancer
Rayner, E., van Gool, I. C., Palles, C., Kearsey, S. E., Bosse, T., Tomlinson, I., & Church, D. N. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.12 · Cited by 373
Bacac, M., Fauti, T., Sam, J., Colombetti, S., Weinzierl, T., Ouaret, D., Bodmer, W., Lehmann, S., Hofer, T., Hosse, R. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1696 · Cited by 345
Innocenti, F., Ou, F.-S., Qu, X., Zemla, T. J., Niedzwiecki, D., Tam, R., Mahajan, S., Goldberg, R. M., Bertagnolli, M. M., Blanke, C. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01798 · Cited by 317
Beatty, G. L., O'Dwyer, P. J., Clark, J., Shi, J. G., Bowman, K. J., Scherle, P. A., Newton, R. C., Schaub, R., Maleski, J., Leopold, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2272 · Cited by 314
Domingo, E., Freeman-Mills, L., Rayner, E., Glaire, M., Briggs, S., Vermeulen, L., Fessler, E., Medema, J. P., Boot, A., Morreau, H., et al. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30014-0 · Cited by 308
Crohn's-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator.
Graham, D. M., & Appelman, H. D. (1990) · PubMed · Cited by 283
Choueiri, T. K., Larkin, J., Oya, M., Thistlethwaite, F., Martignoni, M., Nathan, P., Powles, T., McDermott, D., Robbins, P. B., Chism, D. D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30107-4 · Cited by 260
Greenson, J. K., Bonner, J. D., Ben-Yzhak, O., Cohen, H. I., Miselevich, I., Resnick, M. B., Trougouboff, P., Tomsho, L. D., Kim, E., Low, M., et al. (2003) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200305000-00001 · Cited by 252
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
Linch, S. N., McNamara, M. J., & Redmond, W. L. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00034 · Cited by 238
Stadler, Z. K., Battaglin, F., Middha, S., Hechtman, J. F., Tran, C., Cercek, A., Yaeger, R., Segal, N. H., Varghese, A. M., Reidy-Lagunes, D. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.1067 · Cited by 234
Santini, D., Vincenzi, B., Addeo, R., Garufi, C., Masi, G., Scartozzi, M., Mancuso, A., Frezza, A. M., Venditti, O., Imperatori, M., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr623 · Cited by 211
Gong, J., Wang, C., Lee, P. P., Chu, P., & Fakih, M. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0016 · Cited by 207
Combinations of Bevacizumab With Cancer Immunotherapy
Chen, D. S., & Hurwitz, H. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000327 · Cited by 207
Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma
Lee, L. H., Cavalcanti, M. S., Segal, N. H., Hechtman, J. F., Weiser, M. R., Smith, J. J., Garcia-Aguilar, J., Sadot, E., Ntiamoah, P., Markowitz, A. J., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.139 · Cited by 186
Erratum: Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
Dienstmann, R., Vermeulen, L., Guinney, J., Kopetz, S., Tejpar, S., & Tabernero, J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.24 · Cited by 183
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.
Hellmann, M. D., Kim, T.-W., Lee, C. B., Goh, B.-C., Miller, W. H., Oh, D.-Y., Jamal, R., Chee, C.-E., Chow, L. Q. M., Gainor, J. F., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz113 · Cited by 174
Tabernero, J., Melero, I., Ros, W., Argiles, G., Marabelle, A., Rodriguez-Ruiz, M. E., Albanell, J., Calvo, E., Moreno, V., Cleary, J. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3002 · Cited by 170
Dechant, M., Weisner, W., Berger, S., Peipp, M., Beyer, T., Schneider-Merck, T., Lammerts van Bueren, J. J., Bleeker, W. K., Parren, P. W. H. I., van de Winkel, J. G. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6226 · Cited by 166
Geevarghese, S. K., Geller, D. A., de Haan, H. A., Hörer, M., Knoll, A. E., Mescheder, A., Nemunaitis, J., Reid, T. R., Sze, D. Y., Tanabe, K. K., et al. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.020 · Cited by 163
Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).
Bendell, J. C., Kim, T. W., Goh, B. C., Wallin, J., Oh, D.-Y., Han, S.-W., Lee, C. B., Hellmann, M. D., Desai, J., Lewin, J. H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3502 · Cited by 162
Ribas, A., Hanson, D. C., Noe, D. A., Millham, R., Guyot, D. J., Bernstein, S. H., Canniff, P. C., Sharma, A., & Gomez-Navarro, J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-7-873 · Cited by 161
DNA polymerase delta in dna replication and genome maintenance
Prindle, M. J., & Loeb, L. A. (2012) · Environmental and Molecular Mutagenesis · doi:10.1002/em.21745 · Cited by 140
Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications
Roelands, J. P., Kuppen, P. J. K., Vermeulen, L., Maccalli, C., Decock, J. V., Wang, E., Marincola, F. M., Bedognetti, D., & Hendrickx, W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102229 · Cited by 140
Sun, H.-L., Xin Min, Z. H. O. U., Xue, Y., Wang, K., Shen, Y., Mao, J., Guo, H., & Miao, Z. (2012) · Europe PMC (PubMed Central) · doi:10.3748/wjg.v18.i25.3303 · Cited by 138
Overman, M. J., Ernstoff, M. S., & Morse, M. A. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200821 · Cited by 136
Replicative DNA polymerase mutations in cancer
Heitzer, E., & Tomlinson, I. P. M. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.12.005 · Cited by 122
Petty, J. K., He, K., Corless, C. L., Vetto, J. T., & Weinberg, A. D. (2002) · The American Journal of Surgery · doi:10.1016/s0002-9610(02)00831-0 · Cited by 104
Bendell, J. C., Powderly, J. D., Lieu, C. H., Eckhardt, S. G., Hurwitz, H. I., Höchster, H. S., Murphy, J. E., Funke, R. P., Rossi, C., Wallin, J. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.3_suppl.704 · Cited by 101
Grothey, A. F., Tabernero, J. M., Arnold, D., de Gramont, A., Ducreux, M. P., O'Dwyer, P. J., Cutsem, E. V., Bosanac, I., Srock, S., Mancao, C., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.020 · Cited by 101
Hazama, S., Nakamura, Y., Tanaka, H., Hirakawa, K., TAHARA, K., Shimizu, R., Ozasa, H., Etoh, R., Sugiura, F., Okuno, K., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-108 · Cited by 87
Segal, N. H., Kemeny, N. E., Cercek, A., Reidy‐Lagunes, D. L., Raasch, P. J., Warren, P., Hrabovsky, A. E., Campbell, N. M., Shia, J., Goodman, K. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3539 · Cited by 79
Lenz, H., Cutsem, E. V., Limón, M., Wong, K., Hendlisz, A., Aglietta, M., García-Alfonso, P., Neyns, B., Luppi, G., Cardin, D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.019 · Cited by 71
Hongli, Sun, Xin, Zhou, Yifeng, Xue, Ke, K., Wang, Yunfeng, Y., ShenI, et al. (2012) · Acta Scientiarum Naturalium Universitatis Sunyatseni · Cited by 70
Caballero‐Baños, M., Benítez‐Ribas, D., Tabera, J., Varea, S., Vilana, R., Bianchi, L., Ayuso, J. R., Pagés, M., Carrera, G., Cuatrecasas, M., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.008 · Cited by 58
Takamatsu, M., Hirata, A., Ohtaki, H., Hoshi, M., Ando, T., Ito, H., Hatano, Y., Tomita, H., Kuno, T., Saito, K., et al. (2015) · Cancer Science · doi:10.1111/cas.12705 · Cited by 52
Yamano, T., Kubo, S., Fukumoto, M., Yano, A., Mawatari-Furukawa, Y., Okamura, H., & Tomita, N. (2016) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2016.31 · Cited by 43
Wallin, J. J., Pishvaian, M. J., Hernandez, G., Yadav, M., Jhunjhunwala, S., Delamarre, L., He, X., Powderly, J. D., Lieu, C. H., Eckhardt, S., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-2651 · Cited by 41
Berry, J., Vreeland, T. J., Trappey, A. F., Hale, D. F., Peace, K. M., Tyler, J. A., Walker, A. S., Brown, R. A., Herbert, G. S., Yi, F., et al. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1226132 · Cited by 35
Duffy, A. G., Makarova‐Rusher, O. V., Pratt, D. W., Kleiner, D. E., Fioravanti, S., Walker, M., Carey, S., Figg, W. D., Steinberg, S. M., Anderson, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.560 · Cited by 24
Stein, A., Binder, M., Al‐Batran, S., Hinke, A., Waberer, L., Goekkurt, E., Meyer, T., Statovci, D., Depenbusch, R., Riera‐Knorrenschild, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.3561 · Cited by 24
Research works printed but not linked: 2
- Boucher, 1989, Studies on the control of gene expression of the carcinoembryonic antigen family in human tissue, Cancer Res, 49, 847
- Kooby, 1999, Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207), FASEB J, 13, 1325, 10.1096/fasebj.13.11.1325 · doi:10.1096/fasebj.13.11.1325
Cited by
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Tang, Q., Chen, Y., Li, X., Long, S., Shi, Y., Yu, Y., Wu, W., Han, L., & Wang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.964442 · Cited by 561
Clinical management of metastatic colorectal cancer in the era of precision medicine
Ciardiello, F., Ciardiello, D., Martini, G., Napolitano, S., Tabernero, J., & Cervantes, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21728 · Cited by 528
Self-citationPicard, E., Verschoor, C. P., Ma, G. W., & Pawelec, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00369 · Cited by 522
Patient-derived xenograft models in cancer therapy: technologies and applications
Liu, Y., Wu, W., Cai, C., Zhang, H., Shen, H., & Han, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01419-2 · Cited by 494
Exploring immunotherapy in colorectal cancer
Weng, J., Li, S., Zhu, Z., Liu, Q., Zhang, R., Yang, Y., & Li, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01294-4 · Cited by 355
Metadata
- Authors
- Ciardiello, D., Vitiello, P. P., Cardone, C., Martini, G., Troiani, T., Martinelli, E., & Ciardiello, F.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 76
- Pages
- 22-32
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W2942726985
- Cited by
- 304
- References
- 125
- FWCI
- 16.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- Associazione Italiana per la Ricerca sul Cancro (18972)
- Regione Campania
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.